Cardiometabolic risk in polycystic ovary syndrome: current guidelines

• Autores: Laura G. Cooney, Anuja Dokras
• Localización: Endocrinology and metabolism clinics of North America, ISSN 0889-8529, Vol. 50, Nº. 1, 2021 (Ejemplar dedicado a: Androgens in Women: Too Much, Too Little, Just Right), págs. 83-95
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Polycystic ovary syndrome is a common endocrine disorder in reproductive-aged women and is associated with an increased risk of metabolic abnormalities, including obesity, impaired glucose tolerance, diabetes, dyslipidemia, metabolic syndrome, venous thromboembolism, and subclinical atherosclerosis. Clinicians and patients alike need to be aware of these increased risks as well as new international guidelines that recommend frequent screening and active management of metabolic abnormalities. Given that the data on risk of cardiovascular events, such as myocardial infarction and stroke, in women with PCOS is mixed, future large-scale, longitudinal studies are needed to clarify these potential risks.